IN2014MN01936A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01936A
IN2014MN01936A IN1936MUN2014A IN2014MN01936A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A IN 1936MUN2014 A IN1936MUN2014 A IN 1936MUN2014A IN 2014MN01936 A IN2014MN01936 A IN 2014MN01936A
Authority
IN
India
Prior art keywords
cancer
level
getting
risk
female subject
Prior art date
Application number
Inventor
Andreas Bergmann
Olle Melander
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of IN2014MN01936A publication Critical patent/IN2014MN01936A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Subject matter of the present invention is a method for predicting the risk of getting cancer in a female subject that does not suffer from cancer or alternatively diagnosing cancer in a female subject comprising determining the level of pro neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro neurotensin or fragments thereof with the a risk for getting cancer wherein an elevated level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an elevated level is correlated with the diagnosis of cancer and wherein said cancer is selected from the group comprising breast cancer lung cancer pancreatic cancer and colon cancer.
IN1936MUN2014 2012-03-08 2013-03-08 IN2014MN01936A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261608346P 2012-03-08 2012-03-08
EP12158679 2012-03-08
EP12165054 2012-04-20
PCT/EP2013/054800 WO2013132089A2 (en) 2012-03-08 2013-03-08 A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Publications (1)

Publication Number Publication Date
IN2014MN01936A true IN2014MN01936A (en) 2015-07-10

Family

ID=49117445

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1936MUN2014 IN2014MN01936A (en) 2012-03-08 2013-03-08

Country Status (7)

Country Link
US (2) US20150031144A1 (en)
EP (1) EP2823313B1 (en)
JP (1) JP6290795B2 (en)
CN (1) CN103308689B (en)
IN (1) IN2014MN01936A (en)
RU (1) RU2642623C2 (en)
WO (1) WO2013132089A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324881A1 (en) 2013-12-30 2016-11-10 Oncoprevent Gmbh Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
CN104237535B (en) * 2014-09-30 2016-02-10 天津市泌尿外科研究所 The application of neurotensin in diagnosis castration-resistant prostate cancer neuroendocrine differentiated hypotype and judging prognosis
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
US10900978B2 (en) * 2015-02-27 2021-01-26 Sphingotec Gmbh Method for predicting the risk of obesity in a subject
KR102618553B1 (en) * 2022-08-31 2023-12-27 숙명여자대학교산학협력단 Biomarker for predicting the onset of breast cancer in diabetic patients and prognosis of breast cancer patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
ATE477020T1 (en) 2002-06-07 2010-08-15 Dyax Corp PREVENTION AND REDUCTION OF ISCHEMIA
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005003687A1 (en) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample
WO2007093373A2 (en) * 2006-02-14 2007-08-23 Università Degli Studi Di Siena Branched multimeric peptides for tumor diagnosis and therapy
JPWO2009044561A1 (en) * 2007-10-03 2011-02-03 静岡県 Anti-proNT / NMN monoclonal antibody
ES2373832T3 (en) 2007-12-19 2012-02-09 Affibody Ab POLYPEPTIDE DERIVED FROM PROTEIN A AND ABLE TO JOIN PDGF.
EP2358746B1 (en) 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
US8586043B2 (en) 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
CN102869678A (en) 2009-08-27 2013-01-09 科瓦根股份公司 Il-17 binding compounds and medical uses thereof
CN102753569A (en) 2009-12-14 2012-10-24 塞尔蛋白质股份有限公司 Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
RS58839B1 (en) 2010-06-08 2019-07-31 Pieris Pharmaceuticals Gmbh Tear lipocalin muteins binding il-4 r alpha

Also Published As

Publication number Publication date
US20150031144A1 (en) 2015-01-29
CN103308689B (en) 2017-04-12
US20210109102A1 (en) 2021-04-15
RU2642623C2 (en) 2018-01-25
WO2013132089A3 (en) 2014-02-20
CN103308689A (en) 2013-09-18
WO2013132089A2 (en) 2013-09-12
JP2015512047A (en) 2015-04-23
EP2823313B1 (en) 2019-09-18
JP6290795B2 (en) 2018-03-07
RU2014140432A (en) 2016-04-27
WO2013132089A4 (en) 2014-04-10
EP2823313A2 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2013CN01129A (en)
MX356986B (en) Method for detecting nucleosome adducts.
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
MX2020001156A (en) Method for the prognosis and treatment of cancer metastasis.
MX349561B (en) Method for detecting nucleosomes containing histone variants.
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
IN2014MN01936A (en)
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EP2576837A4 (en) Prostate cancer associated circulating nucleic acid biomarkers
MX368513B (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis.
MX2020010947A (en) Methods of treating alzheimer's disease.
MX2016012285A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
IN2014MN01940A (en)
SG10201808585TA (en) Compositions and methods related to diagnosis of prostate cancer
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
PL2734636T3 (en) Micro-rna biomarkers for identifying risk of and/or for diagnosing lung tumour
NZ729773A (en) Biomarkers for disease progression in melanoma
MA40636A (en) Methods of detecting prostate cancer
EP3385717A3 (en) Methods of detecting prostate cancer
MX2015016305A (en) Predictive biomarker for cancer therapy.
WO2012125805A3 (en) Protein biomarkers for the diagnosis of prostate cancer
WO2016066862A3 (en) A method for predicting the risk of obesity in a subject
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
PL3289096T3 (en) Method for the prognosis and/or diagnosis of an illness based on a sample of adipose tissue